Education
About Us
Working with TipRanks
Follow Us
Travere Therapeutics (TVTX)
NASDAQ:TVTX
Total Valuation
Travere Therapeutics has a market cap or net worth of $2.56B. The enterprise value is $2.81B.
Market Cap$2.56B
Enterprise Value$2.81B
Share Statistics
Travere Therapeutics has 92,241,550 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding92,241,550
Owned by Insiders1.56%
Owned by Institutions37.23%
Financial Efficiency
Travere Therapeutics’s return on equity (ROE) is -0.44 and return on invested capital (ROIC) is -13.92%.
Return on Equity (ROE)-0.44
Return on Assets (ROA)-0.08
Return on Invested Capital (ROIC)-13.92%
Return on Capital Employed (ROCE)-0.14
Revenue Per Employee1.27M
Profits Per Employee-66.35K
Employee Count385
Asset Turnover0.81
Inventory Turnover12.10
Valuation Ratios
The current PE Ratio of Travere Therapeutics is ―. Travere Therapeutics’s PEG ratio is 0.79.
PE Ratio―
PS Ratio6.95
PB Ratio29.69
Price to Fair Value29.69
Price to FCF90.22
Price to Operating Cash Flow66.43
PEG Ratio0.79
Income Statement
In the last 12 months, Travere Therapeutics had revenue of 490.73M and earned -50.26M in profits. Earnings per share was -0.56.
Revenue490.73M
Gross Profit419.65M
Operating Income-62.82M
Pretax Income-49.27M
Net Income-50.26M
EBITDA22.22M
Earnings Per Share (EPS)-0.56
Cash Flow
In the last 12 months, operating cash flow was 37.78M and capital expenditures -11.78M, giving a free cash flow of 26.00M billion.
Operating Cash Flow37.78M
Free Cash Flow26.00M
Free Cash Flow per Share0.28
Dividends & Yields
Travere Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.54
52-Week Price Change33.21%
50-Day Moving Average30.60
200-Day Moving Average25.59
Relative Strength Index (RSI)42.04
Average Volume (3m)1.38M
Important Dates
Travere Therapeutics upcoming earnings date is Apr 30, 2026, After Close (Confirmed).
Last Earnings DateFeb 19, 2026
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
Travere Therapeutics as a current ratio of 2.74, with Debt / Equity ratio of 295.98%
Current Ratio2.74
Quick Ratio2.70
Debt to Market Cap0.10
Net Debt to EBITDA10.61
Interest Coverage Ratio-5.85
Taxes
In the past 12 months, Travere Therapeutics has paid 988.00K in taxes.
Income Tax988.00K
Effective Tax Rate-0.02
Enterprise Valuation
Travere Therapeutics EV to EBITDA ratio is 164.03, with an EV/FCF ratio of 96.46.
EV to Sales7.43
EV to EBITDA164.03
EV to Free Cash Flow96.46
EV to Operating Cash Flow96.46
Balance Sheet
Travere Therapeutics has $322.80M in cash and marketable securities with $339.87M in debt, giving a net cash position of -$17.07M billion.
Cash & Marketable Securities$322.80M
Total Debt$339.87M
Net Cash-$17.07M
Net Cash Per Share-$0.19
Tangible Book Value Per Share$0.01
Margins
Gross margin is 94.20%, with operating margin of -12.80%, and net profit margin of -10.24%.
Gross Margin94.20%
Operating Margin-12.80%
Pretax Margin-10.04%
Net Profit Margin-10.24%
EBITDA Margin4.53%
EBIT Margin-7.85%
Analyst Forecast
The average price target for Travere Therapeutics is $42.73, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$42.73
Price Target Upside53.71% Upside
Analyst ConsensusStrong Buy
Analyst Count14
Revenue Growth Forecast114.22%
EPS Growth Forecast77.02%